Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Market Definition
3.2. Key Drivers
3.2.1. Growing Prevalence Of Kidney Cancer Cases
3.2.2. Increasing Usages Of Minimally Invasive Processes
3.2.3. Surging Research And Development Expenditure
3.3. Key Restraints
3.3.1. High Costs Associated With The Treatment And Diagnosis Of Kidney Cancer
3.3.2. Low Rate Of Success In The Clinical Trials Of Kidney Cancer Drugs
3.3.3. Stringent Regulations

4. Key Analytics
4.1. Porter’S Five Force Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’S Power
4.1.4. Supplier’S Power
4.1.5. Competitive Rivalry
4.2. Impact Of Covid-19 On Kidney Cancer Therapeutics And Diagnostics
4.3. Opportunity Matrix
4.4. Vendor Landscape
4.5. Key Investment Insight

5. Market By Cancer Type
5.1. Clear Cell Rcc
5.2. Papillary Rcc
5.3. Chromophobe Rcc
5.4. Urothelial Carcinoma/Transitional Cell Carcinoma
5.5. Other Kidney Cancers

6. Market By Component
6.1. Drugs
6.1.1. Drugs By Therapeutic Class
6.1.1.1. Targeted Therapy
6.1.1.2. Immunotherapy
6.1.1.3. Other Therapeutic Class
6.1.2. Drugs By Pharmacologic Class
6.1.2.1. Angiogenesis Inhibitors
6.1.2.2. Mtor Inhibitors
6.1.2.3. Monoclonal Antibodies
6.1.2.4. Cytokine Immunotherapy (Il-2)
6.2. Diagnostics
6.2.1. Imaging Test
6.2.2. Biopsy
6.2.3. Blood Test
6.2.4. Other Diagnostics

7. Geographical Analysis
7.1. Europe
7.1.1. Germany
7.1.2. The United Kingdom
7.1.3. France
7.1.4. Italy
7.1.5. Russia
7.1.6. Belgium
7.1.7. Poland
7.1.8. Rest Of Europe

8. Company Profiles
8.1. Abbott Laboratories
8.2. Amgen Inc
8.3. Bayer Ag
8.4. Becton, Dickinson And Company (Bd)
8.5. Bristol-Myers Squibb Company
8.6. Exelixis
8.7. F. Hoffmann-La Roche
8.8. Merck & Co Inc
8.9. Merck Kgaa
8.10. Novartis International Ag
8.11. Nxstage Medical Inc
8.12. Pfizer Inc
8.13. Seattle Genetic



List of Figures


Figure 1: Porter’S Five Force Analysis
Figure 2: Opportunity Matrix
Figure 3: Vendor Landscape
Figure 4: Europe Kidney Cancer Therapeutics And Diagnostics Market, By Cancer Type, In 2019
Figure 5: Europe Kidney Cancer Therapeutics And Diagnostics Market, By Clear Cell Rcc, 2019-2028 (In $ Million)
Figure 6: Europe Kidney Cancer Therapeutics And Diagnostics Market, By Papillary Rcc, 2019-2028 (In $ Million)
Figure 7: Europe Kidney Cancer Therapeutics And Diagnostics Market, By Chromophobe Rcc, 2019-2028 (In $ Million)
Figure 8: Europe Kidney Cancer Therapeutics And Diagnostics Market, By Urothelial Carcinoma/Transitional Cell Carcinoma, 2019-2028 (In $ Million)
Figure 9: Europe Kidney Cancer Therapeutics And Diagnostics Market, By Other Kidney Cancers, 2019-2028 (In $ Million)
Figure 10: Europe Kidney Cancer Therapeutics And Diagnostics Market, By Component, In 2019
Figure 11: Europe Kidney Cancer Therapeutics And Diagnostics Market, By Drugs, 2019-2028 (In $ Million)
Figure 12: Europe Therapeutic Drug Class Market, By Targeted Therapy, 2019-2028 (In $ Million)
Figure 13: Europe Therapeutic Drug Class Market, By Immunotherapy, 2019-2028 (In $ Million)
Figure 14: Europe Therapeutic Drug Class Market, By Other Therapeutic Class, 2019-2028 (In $ Million)
Figure 15: Europe Pharmacologic Class Market, By Angiogenesis Inhibitors, 2019-2028 (In $ Million)
Figure 16: Europe Pharmacologic Class Market, By Mtor Inhibitors, 2019-2028 (In $ Million)
Figure 17: Europe Pharmacologic Class Market, By Monoclonal Antibodies, 2019-2028 (In $ Million)
Figure 18: Europe Pharmacologic Class Market, By Cytokine Immunotherapy (Il-2), 2019-2028 (In $ Million)
Figure 19: Europe Kidney Cancer Therapeutics And Diagnostics Market, By Diagnostics, 2019-2028 (In $ Million)
Figure 20: Europe Diagnostics Market, By Imaging Test, 2019-2028 (In $ Million)
Figure 21: Europe Diagnostics Market, By Biopsy, 2019-2028 (In $ Million)
Figure 22: Europe Diagnostics Market, By Blood Test, 2019-2028 (In $ Million)
Figure 23: Europe Diagnostics Market, By Other Diagnostics, 2019-2028 (In $ Million)
Figure 24: Europe Kidney Cancer Therapeutics And Diagnostics Market, Country Outlook, 2019 & 2028 (In %)
Figure 25: Germany Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 26: The United Kingdom Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 27: France Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 28: Italy Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 29: Russia Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 30: Belgium Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 31: Poland Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)
Figure 32: Rest Of Europe Kidney Cancer Therapeutics And Diagnostics Market, 2019-2028 (In $ Million)


List of Tables


List of Tables


TABLE 1: MARKET SNAPSHOT - KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS
TABLE 2: RISK FACTORS DEVELOPING KIDNEY CANCER
TABLE 3: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 4: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 5: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 6: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 7: EUROPE THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 8: EUROPE THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 9: EUROPE PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 10: EUROPE PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 11: EUROPE DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 12: EUROPE DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 13: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 14: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)